Streetbeat News

Products Services

RARE

Ultragenyx Pharmaceuticals has announced interim Phase 2 Data from its Phase 2/3 Orbit study and issued preliminary Q3 revenue. This has led to an increase in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 3:51 pm

MREO

Mereo BioPharma announced interim Phase 2 Data from the Phase 2/3 Orbit study showing that setrusumab significantly reduced fracture rates in patients with Osteogenesis Imperfecta. This news has led to a rise in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 3:23 pm

VFS

Vietnamese electric vehicle (EV) manufacturer VinFast Auto Ltd (NASDAQ:VFS) is planning to expand into Southeast Asia, starting with Indonesia. The company is on track to achieve its sales projection for the year of 45,000 to 50,000 vehicles. VinFast is also constructing a $2 billion manufacturing complex in North Carolina and plans factories in Indonesia and India. The company expects to break even by the end of 2024 and achieve profitability post-2025.

Portfolio Pulse from Shivani Kumaresan

October 16, 2023 | 3:06 pm

LMT

Lockheed Martin's Next Generation Interceptor (NGI) program has advanced through a major design milestone. The first NGI is forecast for delivery to warfighter as early as FY27.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 3:03 pm

TSLA

Tesla Inc has introduced a new feature called 'Predictive Charger Availability' for its Supercharger network in the U.S. The feature provides Tesla drivers with more precise information about charger availability by predicting how many will be available upon their arrival. The system performs these forecasts by considering the number of Tesla vehicles en route to the same charging station and past activity data related to that specific Supercharger.

Portfolio Pulse from Benzinga EV Insights

October 16, 2023 | 3:00 pm

NFLX

Netflix (NASDAQ:NFLX) is set to release a new series, 'Griselda', depicting the life of Colombian drug lord Griselda Blanco. The series, starring actress Sofía Vergara, will consist of six episodes. The official release date has not been announced, leading to speculations of a 2024 premiere.

Portfolio Pulse from El Planteo

October 16, 2023 | 2:58 pm

AAPL

ALB

AZN

BTCUSD

CVS

HON

MANU

NVAX

NWSA

PFE

RAD

WBA

Bitcoin's price spiked on false rumors of an ETF approval by BlackRock. Albemarle Corporation withdrew its offer to acquire Liontown Resources. Pfizer cut its annual revenue guidance by $9B due to a slump in COVID-19 vaccine sales, and BioNTech warned of €900M write-offs. Rite Aid filed for Chapter 11 bankruptcy. AstraZeneca's Tagrisso-Chemo combo is under FDA priority review. Honeywell projects a 10% increase in new business jet deliveries in 2024. WeWork appointed David Tolley as CEO. Novavax faces a setback as the EMA delays a decision on its COVID-19 vaccine. Activist shareholder Starboard Value acquired a stake in News Corp. Goldman Sachs is reconsidering its consumer lending venture. Manchester United shares fell as the Qatari group pulled away from acquisition. Apple is reshuffling its executive ranks and focusing on reducing the price of Vision Pro. Walgreens and CVS pharmacy staff are planning a nationwide walkout over poor working conditions.

Portfolio Pulse from Vandana Singh

October 16, 2023 | 2:35 pm

GOOGL

Google's latest AI feature, 'Best Take', is revolutionizing digital photography and has been well received by the market, contributing to a 4.8% rise in Alphabet Inc Class A (NASDAQ:GOOGL) stock since October. The stock has broken its September high of $139, showing an annual growth of 52%. If the stock rises just over 10%, it could reach its all-time high of $151.

Portfolio Pulse from Zaheer Anwari

October 16, 2023 | 2:34 pm

RVMD

Revolution Medicines announced preliminary clinical data for RMC-6236 and RMC-6291, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 2:33 pm

AZN

AstraZeneca's supplemental New Drug Application for Tagrisso in combination with chemotherapy has been granted Priority Review by the FDA for locally advanced or metastatic non-small cell lung cancer (NSCLC). The FDA decision is expected in Q1 2024. The application is based on data from the FLAURA2 Phase 3 trial, which showed that the combination reduced the risk of disease progression or death by 38% compared to Tagrisso alone. AstraZeneca's shares are up 0.04% at $67.36.

Portfolio Pulse from Vandana Singh

October 16, 2023 | 2:20 pm